Hosted on MSN

ViiV’s HIV shot preferred, as activists spotlight funding crisis at IAS 2025

ViiV Healthcare’s combination injectable human immunodeficiency virus (HIV) medication was preferred over a daily tablet in treatment-naïve patients in a Phase IIIb trial. A global specialist in HIV ...
Reuters

ViiV expands licence to allow generic HIV treatment production for low-income countries

LONDON, July 14 (Reuters) - ViiV Healthcare, the HIV-focused joint venture majority owned by GSK (GSK.L), opens new tab, said on Monday it has expanded its licensing deal with the Medicines Patent ...
Business Wire

ViiV Healthcare extends voluntary licensing agreement with Medicines Patent Pool to enable access to innovative long-acting injectable HIV treatment

LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced an update to their voluntary licensing ...
Seeking Alpha

ViiV says its HIV PrEP therapy outperformed Gilead’s lenacapavir in early-stage trial

ViiV Healthcare, a healthcare company founded by Pfizer (NYSE:PFE) and GSK (NYSE:GSK), announced on Wednesday that its long-acting HIV PrEP therapy cabotegravir was found to be more acceptable to ...
MM&M

Taking a community approach to HIV awareness the ViiV Healthcare way

ViiV Healthcare’s mission is to raise the profile of HIV across the world and create medicines to more effectively treat the disease. The company’s paramount concerns include elevating the ...